Session Information
Date: Monday, June 5, 2017
Session Title: Epidemiology
Session Time: 1:45pm-3:15pm
Location: Exhibit Hall C
Objective: To observe the effect of Helicobacter pylori eradication on the incidence of Parkinson’s disease
Background: The prevalence of Helicobacter pylori (H. pylori) is high in Parkinson’s disease (PD) patients. H. pylori eradication may improve the motor symptoms and reduce motor fluctuations in Parkinson’s disease (PD). As gut microbiota probably become potential biomarkers in PD and accumulating evidence showed bidirectional interactions between microbiota and nervous system, we intend to explore H. pylori eradication and risk of Parkinson’s disease using a large population-based database.
Methods: We conducted a population-based study on National Health Insurance Database using 1,000,000 represented database from 2000 to 2009. All peptic ulcer patients are separated into two groups: H. pylori eradication patients and non-H. pylori eradication with 1:3 ratio after matching age and gender. H. pylori eradication therapies are recognized effective if patients were treated for at least 14 days. Parkinson’s disease diagnosis is confirmed by regular use of antiparkinsonian medications for at least 3 consecutive neurologist outpatient visits. We then examined risk of PD and H. pylori eradication using multivariable Cox proportional hazards models.
Results: During 6.34-year follow up, we identified 94 (1.2%) of 8098 patients with H. pylori eradication develop PD. The incidence rates (IRs) for PD among H. pylori eradication patients was 1.83 per 1,000 person-year, 1.31 times higher than the rates of non-H. pylori eradication patients. After confounding adjustment, a modest increase in risk for PD was noted with H. pylori eradication patients (Hazard ratio 1.37, 95% CI 1.07 to 1.75).
Conclusions: Our study showed an increased risk of PD for H. pylori eradication patients, compared with non-H. pylori eradication patients. Further studies may elucidate the relationship between H. pylori and PD.
References: 1.Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson’s disease in Denmark. Eur J Neurol 2012; 19: 864–69.
2. Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease—the gut-brain axis and environmental factors.Nat Rev Neurol 2015; 11: 625–36.
To cite this abstract in AMA style:
Y.-P. Chang, G.-F. Chiu, Y.-H. Chang, D.-C. Wu. Helicobacter pylori eradication and risk of Parkinson’s disease in patients with peptic ulcers [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/helicobacter-pylori-eradication-and-risk-of-parkinsons-disease-in-patients-with-peptic-ulcers/. Accessed June 14, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/helicobacter-pylori-eradication-and-risk-of-parkinsons-disease-in-patients-with-peptic-ulcers/